Catalyst

Slingshot members are tracking this event:

Bioverativ(BIVV) plans to initiate a Phase 1/2a of BIVV001 to Treat Hemophilia in the second half of 2017

Source Link:
https://www.bioverativ.com/newsroom/bioverativ-announces-fda-acceptance-of-investigational-new-drug-application-for-bivv001-to-treat-hemophilia-a.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BIVV Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Aug 02, 2017
Occurred Source:
https://www.bioverativ.com/newsroom/bioverativ-reports-second-quarter-2017-performance.aspx
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Bivv001, Phase 1/2a, Hemophilia
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.